fulzerasib   Click here for help

GtoPdb Ligand ID: 12393

Synonyms: Dupert® | GFH925 | IBI351 | structure Z25-2 [WO2021083167A1]
Approved drug
fulzerasib is an approved drug (China NMPA (2024))
Compound class: Synthetic organic
Comment: This is the chemical structure for the INN fulzerasib (a KRAS inhibitor that is intended as an antineoplastic agent). The structure is claimed in patent WO2021083167A1 [2]. Fulzerasib is an orally active small molecule inhibitor of the KRAS G12C oncogenic protein.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

fulzerasib is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 111.35
Molecular weight 616.2
XLogP 4.42
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C=CC(=O)N1CCN2[C@H](C1)C(=O)N(c1c2c2cc(Cl)c(nc2n(c1=O)c1c(C)ccnc1C(C)C)c1c(O)cccc1F)C
Isomeric SMILES [C@H]12CN(CCN1c1c(N(C)C2=O)c(=O)n(c2c1cc(Cl)c(n2)c1c(O)cccc1F)c1c(nccc1C)C(C)C)C(=O)C=C
InChI InChI=1S/C32H30ClFN6O4/c1-6-23(42)38-12-13-39-21(15-38)31(43)37(5)29-28(39)18-14-19(33)26(24-20(34)8-7-9-22(24)41)36-30(18)40(32(29)44)27-17(4)10-11-35-25(27)16(2)3/h6-11,14,16,21,41H,1,12-13,15H2,2-5H3/t21-/m1/s1
InChI Key PYKBFRQMXJWLGG-OAQYLSRUSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
First approval for fulzerasib was granted by the Chinese NMPA in August 2024, to treat advanced NSCLC harbouring the oncogenic KRAS G12C mutation [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05005234 A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations Phase 1/Phase 2 Interventional Innovent Biologics (Suzhou) Co. Ltd.
NCT05756153 A Study of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation Phase 1/Phase 2 Interventional Genfleet Therapeutics (Shanghai) Inc.
NCT05497336 A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer Phase 1 Interventional Innovent Biologics (Suzhou) Co. Ltd.
NCT05504278 Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation Phase 1 Interventional Innovent Biologics (Suzhou) Co. Ltd.